Citi analyst David Lebowitz maintains $PTC Therapeutics (PTCT.US)$ with a sell rating, and maintains the target price at $26.
According to TipRanks data, the analyst has a success rate of 50.6% and a total average return of 1.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $PTC Therapeutics (PTCT.US)$'s main analysts recently are as follows:
PTC Therapeutics recently disclosed Q2 results, with notable sales for Translarna and Emflaza. However, the future of Translarna in EU markets remains uncertain after several adverse opinions from the Committee for Medicinal Products for Human Use (CHMP). A conclusive CHMP opinion is anticipated by mid-October, which could lead to Translarna's withdrawal from the EU market if unfavorable. The success of the company's pipeline programs is deemed essential before contemplating a change in the current analytical outlook.
Estimations are modestly ahead of the consensus regarding Translarna net product revenues and align with expectations on Emflaza net product revenue. Attention is directed towards gaining insights on the CHMP re-examination process and the provision of further details requested by the FDA concerning the NDA re-submission.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
